Crucell N.V.

CRXL

Company. "Crucell is a biotechnology company focused on developing products that prevent and treat infectious diseases.... Today with more than 25 licensees, Crucell's PER.C6® technology is positioned to become the industry standard for the production of vaccines, monoclonal antibodies, therapeutic proteins and gene therapy vectors." (company website)

Buy. Crucell turned up in a screen for bullish breakouts with big volume. The stock has traded in a range between $7 and $9 for most of the year. It finally broke $9 decisively in mid-October when the 50-day moving average crossed over the 200-day moving average.

CRXL broke $10 last week and stayed there, although trading was light. Although the trend is no longer strengthening (black ADX line), there is still a very healthy flow of money into CRXL (CMF).

Sell. Crucell has had a nice run up and the chart still looks quite strong. But, since it has been pulling away from the 50-day moving average for nearly two months now, it is probably time for CRXL to come back toward the average. This sale is simply to lock in the profits.